APT-001 (Spinosad 1.8%) topical therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for APT-001 (Spinosad 1.8%) topical therapy, covering 2025-12-16 to 2025-12-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. [Phase 2]